Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | FABP3 | P05413 | 2/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2727228 | 0.87 | ROCK2 (0.49) | ROCK2FABP3FABP4GABRA1GABRB2 | |
| SCHEMBL30595909 | 0.86 | ROCK2 (0.32) | ROCK2GABRA1GABRB2 | |
| Phosphine SCHEMBL27043067 | 0.85 | ROCK2 (0.48) | ROCK2FABP3FABP4GABRA1GABRB2 | |
| SCHEMBL29424818 | 0.85 | ROCK2 (0.48) | ROCK2FABP3FABP4GABRA1GABRB2 | |
| SCHEMBL30842176 | 0.80 | ROCK2 (0.48) | ROCK2FABP3FABP4GABRA1GABRB2 | |
| Carbimide SCHEMBL27867638 | 0.80 | ROCK2 (0.44) | ROCK2FABP3FABP4GABRA1GABRB2 | |
| SCHEMBL28747511 | 0.76 | ROCK2 (0.42) | ROCK2FABP3FABP4GABRA1GABRB2 | |
| SCHEMBL368977 | 0.72 | FABP3 (0.41) | ROCK2FABP3FABP4GABRA1GABRB2 | |
| SCHEMBL30301693 | 0.72 | ROCK2 (0.42) | ROCK2FABP3FABP4GABRA1GABRB2 | |
| SCHEMBL30159236 | 0.72 | ROCK2 (0.42) | ROCK2FABP3FABP4GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391696-B2 | Pyrrolopyrazole derivatives, preparation method thereof and application thereof in medicine | SHANGHAI MEDICILON INC. (CN) | 2025-08-19 | — | — | US | disclosed |
| WO-2025016899-A1 | SPIROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-23 | — | — | WO | disclosed |
| US-20220281877-A1 | PYRROLOPYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN MEDICINE | MEDICILON PRECLINICAL RESEARCH (SHANGHAI) LLC. (CN) | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281877-A1 | PYRROLOPYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN MEDICINE | ATP1A2, GIPR, PGC | ROCK2 3849/4885FABP3 158/4885FABP4 1115/4885 |
| US-12391696-B2 | Pyrrolopyrazole derivatives, preparation method thereof and application thereof in medicine | ATP1A2, GIPR, PGC | ROCK2 3849/4885FABP3 158/4885FABP4 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.